Evaluation of 14-3-3 protein family levels and associated receptor expression of estrogen and progesterone in Human Uterine Leiomyomas

References

• Stein K, Ascher-Walsh C. A comprehensive approach to the treatment of uterine leiomyomata. Mt Sinai J Med 2009;76:546–556.
   PubMedGoogle Scholar
• Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, Konner J, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009;112:563–567.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008;27:326–332.
   PubMed Web of Science ®Google Scholar
• Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19:16–23.
   PubMed Web of Science ®Google Scholar
• Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203–213.
   PubMed Web of Science ®Google Scholar
• Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006;16:183–192.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260–273.
   PubMed Web of Science ®Google Scholar
• Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc 2007;99:1170–1184.
   PubMed Web of Science ®Google Scholar
• Ohara N. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma. Clin Exp Obstet Gynecol 2005;32:9–11.
   PubMedGoogle Scholar
• Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423–438.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293–307.
   PubMed Web of Science ®Google Scholar
• Mhawech P. 14-3-3 proteins–an update. Cell Res 2005;15:228–236.
   PubMed Web of Science ®Google Scholar
• Martinez JD. 14-3-3 proteins: do they have a role in human cancer? Future Oncol 2005;1:631–633.
   PubMedGoogle Scholar
• Wilker E, Yaffe MB. 14-3-3 Proteins–a focus on cancer and human disease. J Mol Cell Cardiol 2004;37:633–642.
   PubMed Web of Science ®Google Scholar
• Moreira JM, Gromov P, Celis JE. Expression of the tumor suppressor protein 14-3-3 σ is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004;3:410–419.
   PubMed Web of Science ®Google Scholar
• Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma. Oncogene 2000;19:5298–5302.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 σ gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000;60:4353–4357.
   PubMed Web of Science ®Google Scholar
• Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374–381.
   PubMed Web of Science ®Google Scholar
• Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, et al. Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 2002;21:1876–1881.
   PubMed Web of Science ®Google Scholar
• Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004;10:207–220.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010;151:2433–2442.
   PubMed Web of Science ®Google Scholar
• Wango EO, Tabifor HN, Muchiri LW, Sekadde-Kigondu C, Makawiti DW. Progesterone, estradiol and their receptors in leiomyomata and the adjacent normal myometria of black Kenyan women. Afr J Health Sci 2002;9:123–128.
   PubMedGoogle Scholar
• Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037–1054.
   PubMed Web of Science ®Google Scholar